VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vor Biopharma Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$18.04+0.01 (+0.06%)

Close on Oct 19, 2026

Market cap: $979.65M
P/E (TTM): –
Dividend yield: –

Vor Biopharma Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	19	9.85	13	11	4.32	1.34
Change in Accounts Payable	11	2.24	2.85	1.11	0.41	5.82
Operating Cash Flow	-143	-100	-100	-85	-69	-36
Capital Expenditures	-0.94	-0.23	-1.07	-8.46	-3.89	-4.16
Sale of Property, Plant & Equipment	0.80	0	–	–	–	–
Purchase of Investments	-54	-9.91	-75	-123	-88	–
Sale & Maturity of Investments	5.00	107	147	38	–	–
Investing Cash Flow	-49	97	71	-94	-92	-4.16
Dividends Paid	0	0	0	0	0	0
Stock Issued	70	0.28	4.58	4.45	–	–
Taxes Paid on Share-Based Awards	-0.25	-0.33	-1.19	–	–	–
Financing Cash Flow	504	53	2.94	117	233	83
Net Change in Cash	312	51	-26	-62	72	42
Free Cash Flow	-144	-100	-101	-94	-73	-40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 2057.7%

Financial strength

Current ratio: 19.15
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 434.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –